{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "AMLX",
  "name": "Amylyx Pharmaceuticals, Inc.",
  "url": "https://orbyd.app/dossiers/AMLX/",
  "json_url": "https://orbyd.app/dossiers/AMLX.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Single-asset binary: Phase 3 LUCIDITY topline for avexitide in post-bariatric hypoglycemia is guided for late August/early September 2026 (reaffirmed 2026-08-06), while the stock has run 54.9% in three months to within 5.7% of its 52-week high at $22.82. The readout is the entire thesis; everything else is optionality.",
  "invalidation_trigger": "A daily close below $18 (unwinds the bulk of the three-month advance into the readout); secondarily, the company-guided late-August/early-September 2026 LUCIDITY topline window elapsing with no data and no restated timing.",
  "catalyst_date": "2026-08-31",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "binary-catalyst-biotech"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Clinical-stage with no product revenue since RELYVRIO's April 2024 US/Canada withdrawal; quarterly EPS lines carry no commercial signal.",
    "Topline can be released before the open on any business day inside the guided late-August/early-September 2026 window; the event is not calendar-fixed.",
    "Avexitide is a GLP-1 receptor antagonist, the opposite mechanism to semaglutide/tirzepatide; read-across from GLP-1 agonist headlines is unreliable.",
    "A 2026-08-06 wire headline carried cash of $279.8M; the company's Q2 release states $250.8M in cash, equivalents and marketable securities at 2026-06-30."
  ],
  "body_markdown": "## Current Thesis\nAmylyx has become a one-event stock. On 2026-08-06 the company reaffirmed that topline data from the pivotal Phase 3 LUCIDITY trial of avexitide in post-bariatric hypoglycemia (PBH) is \"on track and anticipated in late August or early September 2026.\" Shares closed 2026-08-07 at $22.82, 5.7% below the $24.19 52-week high, after a 54.9% three-month advance with RSI(14) at 74.1. The narrative leg being bought is the de-risking of a Phase 3-ready orphan asset carrying FDA Breakthrough Therapy Designation and a company-described FDA-agreed primary endpoint — and a meaningful share of that de-risking has been paid for in advance of the data.\n\nLife-cycle label: **ACCELERATING**. The dates carrying it are recent and clustered — Mizuho raising its target to $24 on 2026-07-20, Citigroup raising to $26 on 2026-08-03, and the 2026-08-06 guidance reaffirmation that narrowed the readout window from \"Q3 2026\" to a two-week span. Attention is fresh and the price is making new highs; this is not a name with years of mainstream coverage behind it.\n\n## Bull Case\n- **Phase 2b effect size was large.** Avexitide 90 mg once daily produced a 64% least-squares mean reduction in the composite rate of Level 2 and Level 3 hypoglycemic events (Phase 2/2b analyses presented at ENDO 2025, 2025-07-13). LUCIDITY's primary endpoint is that same composite through Week 16.\n- **The readout window is tightly bounded.** LUCIDITY completed enrollment of 78 participants in March 2026, and the Q2 release (2026-08-06) confirmed the last participant's final study visit was complete. The company then guided to late August/early September 2026.\n- **Regulatory standing.** FDA Breakthrough Therapy Designation in both PBH and congenital hyperinsulinism, plus Orphan Drug Designation in hyperinsulinemic hypoglycemia. There is no FDA-approved therapy for PBH today.\n- **No financing gun to the head into the print.** Cash, cash equivalents and marketable securities were $250.8M at 2026-06-30, with a company-stated runway into 2028 covering topline, potential approval and a 2027 launch. NDA-readiness work is running in parallel.\n- **Short base is crowded going in.** Short-interest trackers reported roughly 10.07M shares short, 12.64% of float, up ~14.8% month over month, at 6.1 days to cover (August 2026 settlement data).\n- **Pipeline options are live but unpriced.** AMX0035 Phase 2 HELIOS in Wolfram syndrome showed sustained improvement to Week 96 with Phase 3 planning ongoing with FDA; AMX0114 LUMINA Phase 1 in ALS has Cohorts 1–2 fully enrolled and Cohort 3 (50 mg) enrolling; AMX0318, a long-acting GLP-1 antagonist, is targeted for IND-enabling work in 2027 (all per the 2026-08-06 release).\n\n## Bear Case\n- **Small trial, noisy endpoint.** 78 participants on an event-rate composite in CGM-monitored patients who also manage diet behaviorally. A placebo-arm decline compresses the delta the Phase 2b 64% figure implies.\n- **This management has taken a Phase 3 to the tape and lost.** PHOENIX missed on 2024-03-08; RELYVRIO/ALBRIOZA was voluntarily withdrawn from the US and Canadian markets on 2024-04-04, removing the company's only commercial product.\n- **Published targets sit on top of spot.** Mizuho $24 (2026-07-20) and Citi $26 (2026-08-03) against a $22.82 close on 2026-08-07 leave a thin analyst-anchored cushion.\n- **Cash is burning ahead of any revenue.** Q2 2026 net loss $43.4M, or $(0.39) per share against a $(0.36) consensus; R&D $23.8M, SG&A $21.9M; the balance fell from $316.979M at 2025-12-31 to $250.8M at 2026-06-30 on 111.2M weighted-average shares.\n- **A win is also a financing event.** Funding a 2027 US launch off $250.8M points toward issuance, and biotech equity typically comes to market into strength after positive pivotal data.\n- **Terminal-population question.** Wider GLP-1 agonist use bears on future bariatric-surgery volumes, which are the source population for PBH — a 2028+ concern rather than a 2026 one, but it caps how large the franchise can be modelled.\n\n## Setup & Price Structure\n- Last completed daily close $22.82 (2026-08-07); 52-week high $24.19; -5.7% from that high; +54.9% over three months; RSI(14) 74.1. That is an extended, trending tape arriving at a binary print.\n- The advance has been carried by dated headlines rather than by any change in fundamentals: two price-target raises inside three weeks (2026-07-20, 2026-08-03) and the 2026-08-06 narrowing of readout timing.\n- Positioning observables: an overbought momentum reading, price within 6% of the 52-week high, a rising short base (12.64% of float, +14.8% MoM), and sell-side targets that price has largely caught. The one crowding input that is absent from the record here is insider activity — no Form 4 filings appear in the recent filing set, so nothing is claimed about it.\n- Practical structure note: LUCIDITY topline is a gap event released before the open. Levels drawn before the print carry little information about the price on the day; they matter for the path if data slips or if the readout is ambiguous rather than clean. On that path, a daily close below $18 unwinds the bulk of the three-month advance.\n\n## Catalyst Calendar (next 30 days)\n\n- **~2026-08-31 (est.)** — Phase 3 LUCIDITY topline, avexitide in PBH. Company language, 2026-08-06: \"on track and anticipated in late August or early September 2026.\"\n- **~2026-09-07 (est.)** — outer edge of the guided window. The window closing with no data is itself information, and would put the next timing update on the Q3 call.\n\n## Elapsed catalysts\n\n- No other company-confirmed dated event falls inside the window; Q2 results and the 10-Q landed 2026-08-06. *(passed 3d ago)*\n\n## What Would Change Our Mind\nThe thesis breaks on the endpoint first. A LUCIDITY miss, or a result that separates from placebo only on secondary measures, removes the 2027 launch narrative and re-anchors the company to $250.8M of cash (2026-06-30) plus early-stage pipeline, against 111.2M weighted-average shares. Second, the guided window elapsing: if late August and then early September 2026 pass with no topline and no restated timing, the reason for the summer re-rating has not arrived on schedule and the burden shifts back to the company. Third, the gradeable market condition — a daily close below $18 gives back most of the move that took the stock from mid-teens to $22.82 and would mark the readout being discounted rather than anticipated. Conversely, a clean win on the composite Level 2/3 endpoint with a filing timeline attached would move this from a binary event trade to an execution story, at which point dilution terms and NDA acceptance become the things to watch.\n\n## Correlation Notes\n- Pre-readout the name is close to uncorrelated with the broad tape: the distribution is dominated by one company-specific print inside 30 days. Index beta matters mainly afterwards, when a financing window has to be open.\n- Mechanism read-across is a trap here. Avexitide antagonises the GLP-1 receptor; semaglutide and tirzepatide agonise it. Headlines that move the GLP-1 agonist complex do not carry clean information about this asset, though they do inform long-run bariatric-procedure volumes.\n- Sensitivity to XBI-style small-cap biotech risk appetite is real but second-order until the data is out; it becomes first-order on the day terms for any post-data offering are set.\n- The ALS association is legacy. AMX0114 is a Phase 1 asset; co-movement with ALS-sector headlines should be treated as sentiment rather than as valuation-relevant.",
  "first_seen": "2026-08-07",
  "last_analyzed": "2026-08-09T08:10:09+00:00",
  "last_synthesized": "2026-08-08",
  "last_update_source": "theme_discovery",
  "license": "Content © orbyd. Cite the canonical URL."
}